Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria

Inclusion Criteria: For Part 1 and 2 of the study design, all individuals must meet all the inclusion criteria below: * Patients diagnosed with symptomatic mild to moderate P. falciparum malaria with a parasite density of \>= 5000 parasites/μl * Adult male, age 18-55 years old or adult female, age 18-55 years that are post-menopausal, or test negative on a pregnancy test and will be on active birth control through to the end of the follow up period. * Provision of informed consent and agrees to hospital admission for 48-72hrs * Good health condition other than malaria * The patient has not taken anti-malarial drugs in the past 4 weeks For Part 3 of the trial, all individuals must meet all the inclusion criteria below: * Patients diagnosed with symptomatic mild to moderate P. falciparum malaria and a parasite density of \>= 5000 parasites/μl * Age 12 months to below 18 years * Presented by parent or legally accepted representative (LAR) who has consented to the participation of the child in the trial and agrees to hospital admission for 48-72hrs. * Hb levels \> 5mg/dL * Child has not taken anti-malarial drugs in the past 6 weeks. Exclusion Criteria: * Prospective study participant, LAR and/or impartial witness (where applicable) declines to provide informed consent. * Symptoms and signs of severe or complicated malaria including: * significant confusion or impaired consciousness (including unarousable coma) * multiple convulsions (more than two episodes within 24 ho…